Literature DB >> 9774608

Evaluation of a leukocyte stabilization reagent for use in the cytomegalovirus pp65 antigenemia assay.

C E Bush1, J A Sluchak-Carlsen.   

Abstract

New erythrocyte lysis and leukocyte stabilization reagents (Streck Laboratories, Inc.) were tested in the cytomegalovirus pp65 antigenemia assay, to determine if whole-blood processing time could be delayed to 24 h postdraw. The combination of these reagents gave results comparable to those for patient samples processed immediately after blood draw.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9774608      PMCID： PMC105344     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  11 in total

1.  Effect of delayed specimen processing on cytomegalovirus antigenemia test results.

Authors:  M L Landry; D Ferguson; S Cohen; K Huber; P Wetherill
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

Review 2.  Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.

Authors:  M A Jacobson
Journal:  N Engl J Med       Date:  1997-07-10       Impact factor: 91.245

3.  High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up.

Authors:  B Bek; M Boeckh; J Lepenies; B Bieniek; K Arasteh; W Heise; K M Deppermann; G Bornhöft; M Stöffler-Meilicke; I Schuller; G Höffken
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

4.  Comparison of PCR and pp65 antigenemia assay with quantitative shell vial culture for detection of cytomegalovirus in blood leukocytes from solid-organ transplant recipients.

Authors:  G A Storch; R S Buller; T C Bailey; N A Ettinger; T Langlois; M Gaudreault-Keener; P L Welby
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

Review 5.  Consequences for the management of cytomegalovirus.

Authors:  C Katlama
Journal:  AIDS       Date:  1996-11       Impact factor: 4.177

6.  Surveillance of cytomegalovirus after solid-organ transplantation: comparison of pp65 antigenemia assay with a quantitative DNA hybridization assay.

Authors:  W Bossart; K Bienz; W Wunderli
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

Review 7.  Clinical impact of cytomegalovirus infections of the nervous system in patients with AIDS.

Authors:  J A McCutchan
Journal:  Clin Infect Dis       Date:  1995-10       Impact factor: 9.079

8.  Cytomegalovirus (CMV) antigenemia assay is more sensitive than shell vial cultures for rapid detection of CMV in polymorphonuclear blood leukocytes.

Authors:  A Erice; M A Holm; P C Gill; S Henry; C L Dirksen; D L Dunn; R P Hillam; H H Balfour
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

Review 9.  Cytomegalovirus infections in renal, heart, heart-lung and liver transplantation.

Authors:  R B Pollard
Journal:  Pediatr Infect Dis J       Date:  1988-05       Impact factor: 2.129

10.  Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia.

Authors:  G Gerna; M G Revello; E Percivalle; F Morini
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948
View more
  2 in total

1.  Leukocyte stabilization reagent for use in the cytomegalovirus pp65 antigenemia assay.

Authors:  S M Lipson
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

Review 2.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.